Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) focused on biologics, vaccines, advanced therapies, and oncolytic viruses, has launched the first phase of its expansion at the Hillerød, Denmark site, bringing the new production capacity into operation.
 
This milestone marks the initial step in the company’s strategy to build a comprehensive global ecosystem dedicated to enhancing the production and delivery of medicines.
 
This first phase adds six mammalian cell bioreactors, bringing the total capacity at the Hillerød site to 12 x 20,000 L bioreactors. A previously announced major capital investment will support the next phase, which will include an additional 8 x 20,000 L bioreactors and two downstream processing streams. By mid-2025, fill/finish production is scheduled to commence, with full expansion expected to be in operation by 2026, increasing the site footprint to approximately 51,500 m² and creating up to 2,200 jobs.
 
Since 2011, Fujifilm Corporation has invested over $8 billion to establish a formidable global network for biologics manufacturing. This includes strategically located modular facilities designed to provide the agility needed for rapid production scaling. In 2025, operations will begin at the first phase of Fujifilm Diosynth Biotechnologies’ large-scale facility in Holly Springs, North Carolina, further reinforcing the company’s commitment to building its transformative ecosystem.
 
“The Hillerød facility is the first expansion in our global network, which will include further developments in the US, UK, and Japan,” said Lars Petersen, President and Chief Executive Officer of Fujifilm Diosynth Biotechnologies. “By investing in state-of-the-art facilities on both sides of the Atlantic and prioritizing our workforce, we are uniquely positioned to meet the evolving needs of our partners and the patients they serve.”